United States Government Publishing Office
publisher
pbl
distributor
dst
United States
National Archives and Records Administration
Office of the Federal Register
author
aut
Government Organization
text
government publication
eng
FR
Regulatory Information
2019_register
executive
2019-10-26
article
Prospective Grant of an Exclusive Patent License: The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment of GPC3-Expressing Cancers
Notices
D09002ee1bdb6b3ca
D09002ee1bdb6b445
United States
Department of Health and Human Services
originator
org
United States Government Agency or Subagency
United States
National Institutes of Health
originator
org
United States Government Agency or Subagency
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Xsto BioSciences, Inc. (Xsto), located in San Carlos, California.
84 FR 57743
https://www.govinfo.gov/app/details/FR-2019-10-28/2019-23481
2019-23481
fr28oc19-71
4140-01-P
https://www.govinfo.gov/app/details/FR-2019-10-28/2019-23481
https://www.govinfo.gov/content/pkg/FR-2019-10-28/html/2019-23481.htm
https://www.govinfo.gov/content/pkg/FR-2019-10-28/pdf/2019-23481.pdf
2 p.
57743
57744
84 FR 57743
Prospective Grant of an Exclusive Patent License: The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment of GPC3-Expressing Cancers; Federal Register Vol. 84, Issue
NOTICE
2019-23481
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
2019-11-12
4140-01-P
2019-23481
Notice.
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this notice to Xsto BioSciences, Inc. (Xsto), located in San Carlos, California.
Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before November 12, 2019 will be considered.
Prospective Grant of an Exclusive Patent License:
The Development of an Anti-GPC3 Radionuclide Immunoconjugate for the Treatment of GPC3-Expressing Cancers
,
david.lambertson@nih.gov
Federal Register
Vol. 84, no. 208
Office of the Federal Register, National Archives and Records Administration
2019-10-28
continuing
daily
deposited
born digital
222 p.
Table of Contents:
AE 2.7:
GS 4.107:
AE 2.106:
KF70.A2
https://www.govinfo.gov/app/details/FR-2019-10-28
P0b002ee1a35cb23a
0097-6326
0042-1219
0364-1406
769-004-00000-9
000582072
f:fr28oc19
https://www.govinfo.gov/app/details/FR-2019-10-28
https://www.govinfo.gov/content/pkg/FR-2019-10-28/pdf/FR-2019-10-28.pdf
https://www.govinfo.gov/content/pkg/FR-2019-10-28/xml/FR-2019-10-28.xml
fdlp
57601
57811
DGPO
2019-10-26
2023-04-28
FR-2019-10-28
machine generated
eng
FR
FR-2019-10-28
84
208